Spiramycin

Summary

Spiramycin (CHEMBL6195749) is an approved small molecule (ATC J01FA02); indicated across 2 conditions including bacterial infectious disease and congenital toxoplasmosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01FA02
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6195749
Name	Spiramycin
Type	Small molecule
Max phase	4
ATC	J01FA02

Also known as: Acetylspiramycin, Espiramicina, IL 5902, IL-5902, NSC-55926, NSC-64393, NSC-758472, Rovamicina, Rovamycin, Rovamycine, Rovamycine 250, RP 5337

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
congenital toxoplasmosis	3	MONDO:0005715	EFO:0007220

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004317	PHASE4	RECRUITING	Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
NCT01189448	PHASE3	COMPLETED	Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy
NCT00000980	PHASE1	COMPLETED	A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea
NCT00002062	Not specified	COMPLETED	Open-Label Compassionate Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).